skip to Main Content

OBIND – Oncological therapies through Biological Interaction Network Discovery

Project title: OBIND: Oncological therapies through Biological Interaction Network Discovery

Start/end date: 15/01/2020 – 30/04/2023

Financing Agency/Programme: Regione Siciliana. PO FESR 2014/2020 – – Obiettivo Tematico 1 Ricerca, Sviluppo Tecnologico e Innovazione, Obiettivo specifico 1.1 – Incremento dell’attività di innovazione delle imprese, Azione 1.1.5 – Sostegno all’avanzamento tecnologico delle imprese attraverso il finanziamento di linee pilota e azioni di validazione precoce dei prodotti e di dimostrazione su larga scala.

Partnership: Exprivia S.p.A. – (coordinator); Università degli Studi di Palermo; Fondazione Ri.MED; Securproject; OS2; 2038 Innovation Company; IRIB-CNR.

Abstract: OBIND goal is to develop a computerised system in the oncology field which allows for aggregation and analysis of different data sets, focused on studying the interaction between different biological molecules that are found to have changed in tumour diseases and in order to create a rational outline for planning new treatments. The study of complex diseases, such as tumours, requires an integrated data analysis approach. In addition to analysing the genes involved in the transformation process of normal cells into tumour cells (over 500 have been identified), the study of the onset of a tumour also requires analysis of the interactions between proteins, RNA and small molecules. Pharmaceutical planning of new specialised and personalised anti-tumour treatments is a highly complex process; in fact, the development of new chemical entities (NCEs), takes on average 13 years with costs approaching one billion euros. Studying the behaviour of the entire network of molecular interactions means the effects of a treatment can be predicted on a broader scale than a single interaction. This analysis first requires consultation of specialised databases available on the internet or from research bodies. The problems related to analysing the data required to study tumours and developing new drugs are several: the large quantity of biomedical data is difficult to consult and process; its fragmentary nature prevents an overall view of the problems associated with the disease; and the many different formats or lack of structure result in poor interoperability.
The research and development plan sets out to optimise:

  • data selection for the study of the tumour diseases concerned, using a semantic search engine connected to the main databases of proteomics, transcriptomics, interatomics, chemogenomics, structural biology and medical chemistry;
  • integrated analysis of different types of data, in order to identify biological interactions between small molecules, RNA and proteins, which affect, or may affect, the onset, development and/or the regression of a tumour;
  • use of new statistical and computational approaches involved in data processing and integrated analysis models for a number of data sources;
  • extrapolation of patented structural information (scaffold) to be included in the planning workflow of new treatments

Principal Investigator: Ugo Perricone e Claudia Coronnello

Output: 
Piattaforma per lo studio di network molecolari (Proteina-ligando, proteina-proteina) e predizione attività su Kinasi coinvolte in processi tumorali.

Scientific products: 

 

Download the OBIND poster

Back To Top